Alexandra Rojek, MD is a hematologist/oncologist specializing in the care of adults with lymphoma and has a particular interest in the use of chimeric antigen receptor (CAR) T-cell therapy in the treatment of lymphoma patients. She has expertise in the treatment of non-Hodgkin lymphomas, Hodgkin lymphoma, T cell lymphomas, and the role of stem cell transplantation in the treatment of different lymphomas in addition to CAR T cell therapy. Dr. Rojek’s laboratory research focuses on identifying immunology mechanisms underlying the success of cellular therapies and developing strategies to leverage these mechanisms to improve cellular therapy efficacy for patients. Her research aims to then translate these findings into early phase trials utilizing cellular therapies for patients with lymphoma as well as other malignancies.
Tumor-infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions.
Tumor-infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions. Cancer. 2026 Aug 01; 132(15):e70526.
PMID: 42482408
Outcomes and Safety of CAR-T Cell Therapy in B-NHL Patients With Reduced Left Ventricular Ejection Fraction.
Outcomes and Safety of CAR-T Cell Therapy in B-NHL Patients With Reduced Left Ventricular Ejection Fraction. Transplant Cell Ther. 2026 Oct; 32(10):1240.e1-1240.e5.
PMID: 42217793
Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.
Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study. Blood Cancer J. 2026 03 23; 16(1).
PMID: 41872135
Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.
Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight. Hematology Am Soc Hematol Educ Program. 2025 12 05; 2025(1):334-341.
PMID: 41348051
Prognosis and Treatment of Plasmablastic Lymphoma in the United States: A Multicenter Retrospective Study.
Prognosis and Treatment of Plasmablastic Lymphoma in the United States: A Multicenter Retrospective Study. Res Sq. 2025 Sep 30.
PMID: 41255989
Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study.
Karyotypic clonal fraction predicts adverse outcome in TP53-mutated myeloid neoplasms: an International TP53 investigators Network (iTiN) study. J Clin Pathol. 2025 Aug 18; 78(9):629-635.
PMID: 40571403
Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma-Results from a multicenter cohort study.
Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma-Results from a multicenter cohort study. Blood Cancer J. 2025 06 21; 15(1):110.
PMID: 40544154
Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study.
Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study. Am J Hematol. 2025 Jun; 100(6):1082-1085.
PMID: 40062542
Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia.
Real-world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia. EJHaem. 2024 Aug; 5(4):728-737.
PMID: 39157611
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience.
CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Adv. 2024 07 09; 8(13):3528-3531.
PMID: 38701405